Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
Sponsor: Masonic Cancer Center, University of Minnesota
Summary
This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure. The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines.
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2014-10-06
Completion Date
2032-01-30
Last Updated
2026-01-06
Healthy Volunteers
No
Interventions
Fludarabine
Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
Cyclophosphamide
Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
Total Body Irradiation
TBI 200cGy in a single fraction on day -1 from transplant.
Hematopoietic stem cell infusion
Hematopoietic stem cell infusion given on day 0.
Locations (1)
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota, United States